Abstract
Cervical carcinoma is worldwide the third most frequent carcinoma affecting women; regionally, it is sometimes even the most frequent form of female cancer. Moreover, anogenital dysplasia and genital warts represent a major health care problem. With the development of bivalent and quadrivalent prophylactic vaccines against HPV 16 and 18 or HPV 6, 11, 16 and 18, respectively, a very promising immunoprophylaxis is now available to prevent the development of HPV-associated diseases and in particular, cervical carcinoma.
MeSH terms
-
Adolescent
-
Adult
-
Child
-
Family Practice
-
Female
-
Germany
-
Humans
-
Immunization Programs / economics
-
Insurance Coverage / economics
-
Male
-
National Health Programs / economics
-
Papillomavirus Infections / diagnosis
-
Papillomavirus Infections / prevention & control*
-
Papillomavirus Infections / transmission
-
Papillomavirus Vaccines / administration & dosage*
-
Papillomavirus Vaccines / economics
-
Patient Education as Topic
-
Uterine Cervical Neoplasms / diagnosis
-
Uterine Cervical Neoplasms / etiology
-
Uterine Cervical Neoplasms / prevention & control*
-
Vaginal Smears / economics